Management ChangeJun 12, 2026, 04:28 PM
Ocular Therapeutix Appoints Jason Robins as CFO; Boosts Stock Plan Shares
AI Summary
Ocular Therapeutix, Inc. announced the appointment of Jason Robins as its permanent Chief Financial Officer, effective June 10, 2026. His compensation package includes an annual base salary of $535,100, a target annual cash bonus of 45% of his base, and equity awards comprising 14,024 stock options and 15,441 restricted stock units. Additionally, stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the number of shares issuable by 10,000,000. At the 2026 Annual Meeting, stockholders also re-elected two Class III directors and approved executive compensation on an advisory basis.
Key Highlights
- Jason Robins appointed permanent Chief Financial Officer.
- CFO's annual base salary increased to $535,100 starting July 1, 2026.
- CFO's annual cash bonus targeted at 45% of annual base salary.
- CFO granted 14,024 stock options and 15,441 restricted stock units.
- Stockholders approved increasing 2021 Stock Incentive Plan shares by 10,000,000.
- Pravin U. Dugel, M.D. and Merilee Raines elected as Class III directors.
- Stockholders approved named executive officer compensation on advisory basis.
- Stockholders approved "One Year" frequency for future advisory votes on executive compensation.
Price Impact
More from OCUL